Outpatient CAR-T therapy in adult hematologic malignancies: Systematic review of feasibility, toxicity, hospitalization, and resource use
Electronic Journal of General Medicine · 21.07.2026 · 23 (4) · em744
DOI: 10.29333/ejgm/18988 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Electronic Journal of General Medicine, erschienen am 21.07.2026. Verfasst von Marat Shoranov und 7 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Background
Outpatient and ambulatory models of chimeric antigen receptor T-cell (CAR-T) therapy have been developed to reduce inpatient bed use and improve patient-centered delivery. However, safety and feasibility are difficult to interpret because published evidence differs by CAR-T product, costimulatory domain, disease context, monitoring pathway, and definition of outpatient care.
Objective
To synthesize evidence on feasibility, toxicity, hospitalization burden, intensive care use, healthcare resource utilization, and cost-related outcomes associated with outpatient CAR-T therapy in adults with hematologic malignancies.
Methods
A PRISMA-structured systematic review was conducted using PubMed/MEDLINE, Web of Science core collection, Scopus, and Cochrane CENTRAL for studies published from 1 January 2017 to 1 January 2026. Eligible studies included adults receiving CAR-T therapy in outpatient infusion, ambulatory monitoring, early-discharge, telemedicine-supported, remote-monitoring, or community-site pathways and reported extractable clinical or resource-use outcomes. Meta-analysis was not performed because of heterogeneity; synthesis followed SWiM principles.
Results
Twelve original studies published from 2022 to 2025 were included. Selected 4-1BB-based pathways showed the clearest signal for admission avoidance: in one tisa-cel cohort, 68 of 72 patients were managed outpatient and 36.1% were admitted within 30 days; in the multicenter tisa-cel cohort, 45% of outpatient recipients required unplanned admission. OUTREACH showed feasible community-site liso-cel monitoring, with 70% monitored outpatient and 25% of outpatient-monitored patients never hospitalized. CD28-based outpatient axi-cel/brexu-cel pathways were feasible but often still led to admission: in a prospective outpatient axi-cel trial, 19 of 20 patients were admitted within four weeks, and in ZUMA-24, 93% were hospitalized after outpatient axi-cel. Claims analyses suggested lower index or 30-day costs for outpatient site of care, but they lacked toxicity grading and detailed pathway information.
Conclusions
Outpatient CAR-T therapy is feasible for carefully selected adults, but outpatient initiation should not be equated with hospital-free treatment. Current evidence supports structured, product- and risk-adapted outpatient programs rather than unselected ambulatory administration.
Zitieren
APA
Shoranov, M., Fakhradiyev, I., Tanabayeva, S., Menlayakova, D., Keyer, V., Kydyrbayeva, A., Zhumabekova, M., & Shustov, A. (2026). Outpatient CAR-T therapy in adult hematologic malignancies: Systematic review of feasibility, toxicity, hospitalization, and resource use. Electronic Journal of General Medicine, 23(4), em744. https://doi.org/10.29333/ejgm/18988
Vancouver
Shoranov M, Fakhradiyev I, Tanabayeva S, Menlayakova D, Keyer V, Kydyrbayeva A, et al. Outpatient CAR-T therapy in adult hematologic malignancies: Systematic review of feasibility, toxicity, hospitalization, and resource use. Electronic Journal of General Medicine. 2026;23(4):em744. doi:10.29333/ejgm/18988
BibTeX
@article{Shoranov2026,
author = {Shoranov, Marat and Fakhradiyev, Ildar and Tanabayeva, Shynar and Menlayakova, Darina and Keyer, Viktoriya and Kydyrbayeva, Aitolkyn and Zhumabekova, Maral and Shustov, Alexandr},
title = {Outpatient CAR-T therapy in adult hematologic malignancies: Systematic review of feasibility, toxicity, hospitalization, and resource use},
journal = {Electronic Journal of General Medicine},
year = {2026},
volume = {23},
number = {4},
pages = {em744},
doi = {10.29333/ejgm/18988}
}
EUVIMED